bbT-369

N/A

Report date: 2025/10/22 20:00:56

Base Information

Drug NamebbT-369
Drug Alias NamebbT-369
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityB-cell antigen receptor complex-associated protein alpha chain inhibitors +[4] 
TargetsB-cell antigen receptor complex-associated protein alpha chainB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGenetix Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenetix Biotherapeutics Inc
Inactive CompaniesRegeneron Pharmaceuticals Inc
Active IndicationsLymphoma, Non-Hodgkin
Inactive IndicationsLymphoma, Large B-Cell, Diffuse

Other Information

ATC CodeN/A
Related LinksN/A